Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Diagnostic Bedside Ultrasound Program Development in Pediatric Critical Care Medicine: Results of a National Survey.

Conlon TW, Kantor DB, Su ER, Basu S, Boyer DL, Haileselassie B, Petersen TL, Su F, Nishisaki A.

Pediatr Crit Care Med. 2018 Aug 14. doi: 10.1097/PCC.0000000000001692. [Epub ahead of print]

PMID:
30113518
2.

Effectiveness of alternative dose fingolimod for multiple sclerosis.

Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von Geldern G, Chahin S, Cross AH, Parks BJ, Rice M, Khoury SJ, Yamout B, Zeineddine M, Russell-Giller S, Caminero-Rodriguez A, Edwards K, Lathi E, VanderKodde D, Meador W, Berkovich R, Ge L, Bacon TE, Kister I.

Neurol Clin Pract. 2018 Apr;8(2):102-107. doi: 10.1212/CPJ.0000000000000434.

PMID:
29708225
3.

Transcutaneous CO-oximetry differentiates asthma exacerbation and convalescence in children.

Kantor DB, Petty CR, Phipatanakul W, Gaffin JM.

J Allergy Clin Immunol. 2018 Aug;142(2):676-678.e5. doi: 10.1016/j.jaci.2018.02.048. Epub 2018 Apr 16. No abstract available.

PMID:
29673798
4.

Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis.

Kantor D, Johnson K, Vieira MC, Signorovitch J, Li N, Gao W, Koo V, Duchesneau E, Herrera V.

J Neurol Sci. 2018 May 15;388:168-174. doi: 10.1016/j.jns.2018.03.018. Epub 2018 Mar 10.

PMID:
29627016
5.

Fluid Balance Is Associated with Clinical Outcomes and Extravascular Lung Water in Children with Acute Asthma Exacerbation.

Kantor DB, Hirshberg EL, McDonald MC, Griffin J, Buccigrosso T, Stenquist N, Smallwood CD, Nelson KA, Zurakowski D, Phipatanakul W, Hirschhorn JN.

Am J Respir Crit Care Med. 2018 May 1;197(9):1128-1135. doi: 10.1164/rccm.201709-1860OC.

PMID:
29313715
6.

Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks.

Demenais F, Margaritte-Jeannin P, Barnes KC, Cookson WOC, Altmüller J, Ang W, Barr RG, Beaty TH, Becker AB, Beilby J, Bisgaard H, Bjornsdottir US, Bleecker E, Bønnelykke K, Boomsma DI, Bouzigon E, Brightling CE, Brossard M, Brusselle GG, Burchard E, Burkart KM, Bush A, Chan-Yeung M, Chung KF, Couto Alves A, Curtin JA, Custovic A, Daley D, de Jongste JC, Del-Rio-Navarro BE, Donohue KM, Duijts L, Eng C, Eriksson JG, Farrall M, Fedorova Y, Feenstra B, Ferreira MA; Australian Asthma Genetics Consortium (AAGC) collaborators, Freidin MB, Gajdos Z, Gauderman J, Gehring U, Geller F, Genuneit J, Gharib SA, Gilliland F, Granell R, Graves PE, Gudbjartsson DF, Haahtela T, Heckbert SR, Heederik D, Heinrich J, Heliövaara M, Henderson J, Himes BE, Hirose H, Hirschhorn JN, Hofman A, Holt P, Hottenga J, Hudson TJ, Hui J, Imboden M, Ivanov V, Jaddoe VWV, James A, Janson C, Jarvelin MR, Jarvis D, Jones G, Jonsdottir I, Jousilahti P, Kabesch M, Kähönen M, Kantor DB, Karunas AS, Khusnutdinova E, Koppelman GH, Kozyrskyj AL, Kreiner E, Kubo M, Kumar R, Kumar A, Kuokkanen M, Lahousse L, Laitinen T, Laprise C, Lathrop M, Lau S, Lee YA, Lehtimäki T, Letort S, Levin AM, Li G, Liang L, Loehr LR, London SJ, Loth DW, Manichaikul A, Marenholz I, Martinez FJ, Matheson MC, Mathias RA, Matsumoto K, Mbarek H, McArdle WL, Melbye M, Melén E, Meyers D, Michel S, Mohamdi H, Musk AW, Myers RA, Nieuwenhuis MAE, Noguchi E, O'Connor GT, Ogorodova LM, Palmer CD, Palotie A, Park JE, Pennell CE, Pershagen G, Polonikov A, Postma DS, Probst-Hensch N, Puzyrev VP, Raby BA, Raitakari OT, Ramasamy A, Rich SS, Robertson CF, Romieu I, Salam MT, Salomaa V, Schlünssen V, Scott R, Selivanova PA, Sigsgaard T, Simpson A, Siroux V, Smith LJ, Solodilova M, Standl M, Stefansson K, Strachan DP, Stricker BH, Takahashi A, Thompson PJ, Thorleifsson G, Thorsteinsdottir U, Tiesler CMT, Torgerson DG, Tsunoda T, Uitterlinden AG, van der Valk RJP, Vaysse A, Vedantam S, von Berg A, von Mutius E, Vonk JM, Waage J, Wareham NJ, Weiss ST, White WB, Wickman M, Widén E, Willemsen G, Williams LK, Wouters IM, Yang JJ, Zhao JH, Moffatt MF, Ober C, Nicolae DL.

Nat Genet. 2018 Jan;50(1):42-53. doi: 10.1038/s41588-017-0014-7. Epub 2017 Dec 22.

7.

Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Patient Education.

Kantor D, Bright JR, Burtchell J.

Neurol Ther. 2018 Jun;7(1):23-36. doi: 10.1007/s40120-017-0087-3. Epub 2017 Dec 14.

8.

Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Participatory Medicine.

Kantor D, Bright JR, Burtchell J.

Neurol Ther. 2018 Jun;7(1):37-49. doi: 10.1007/s40120-017-0088-2. Epub 2017 Dec 8.

9.

Gene-Environment Interactions Associated with the Severity of Acute Asthma Exacerbation in Children.

Kantor DB, Phipatanakul W, Hirschhorn JN.

Am J Respir Crit Care Med. 2018 Mar 1;197(5):545-547. doi: 10.1164/rccm.201711-2166ED. No abstract available.

PMID:
29160726
10.

Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.

Bell C, Anderson J, Ganguly T, Prescott J, Capila I, Lansing JC, Sachleben R, Iyer M, Fier I, Roach J, Storey K, Miller P, Hall S, Kantor D, Greenberg BM, Nair K, Glajch J.

J Pharm Pract. 2017 Jan 1:897190017725984. doi: 10.1177/0897190017725984. [Epub ahead of print]

PMID:
28847230
11.

Ultrasound Measurement of Muscle Thickness: A Novel Biomarker for the PICU?

Kantor DB, Mehta NM.

Pediatr Crit Care Med. 2017 Aug;18(8):817-819. doi: 10.1097/PCC.0000000000001245. No abstract available.

PMID:
28796713
12.

Safety and efficacy of dual-lead thalamic deep brain stimulation for patients with treatment-refractory multiple sclerosis tremor: a single-centre, randomised, single-blind, pilot trial.

Oliveria SF, Rodriguez RL, Bowers D, Kantor D, Hilliard JD, Monari EH, Scott BM, Okun MS, Foote KD.

Lancet Neurol. 2017 Sep;16(9):691-700. doi: 10.1016/S1474-4422(17)30166-7. Epub 2017 Jun 20.

PMID:
28642125
13.

Two decades of glatiramer acetate: From initial discovery to the current development of generics.

Weinstock-Guttman B, Nair KV, Glajch JL, Ganguly TC, Kantor D.

J Neurol Sci. 2017 May 15;376:255-259. doi: 10.1016/j.jns.2017.03.030. Epub 2017 Mar 21. Review.

14.

Reply.

Kantor DB, Phipatanakul W, Hirschhorn JN.

J Allergy Clin Immunol. 2017 May;139(5):1717-1718. doi: 10.1016/j.jaci.2016.11.054. Epub 2017 Mar 6. No abstract available.

15.

Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate.

D Alessandro J, Garofalo K, Zhao G, Honan C, Duffner J, Capila I, Fier I, Kaundinya G, Kantor D, Ganguly T.

CNS Neurol Disord Drug Targets. 2017;16(6):714-723. doi: 10.2174/1871527316666170223162747.

16.

Omalizumab Is Associated with Reduced Acute Severity of Rhinovirus-triggered Asthma Exacerbation.

Kantor DB, McDonald MC, Stenquist N, Schultz BJ, Smallwood CD, Nelson KA, Phipatanakul W, Hirschhorn JN.

Am J Respir Crit Care Med. 2016 Dec 15;194(12):1552-1555. No abstract available.

17.

Long-Gap Esophageal Atresia Is a Unique Entity within the Esophageal Atresia Defect Spectrum.

Bairdain S, Zurakowski D, Vargas SO, Stenquist N, McDonald M, Towne MC, Miller DT, Jennings RW, Kantor DB, Agrawal PB.

Neonatology. 2017;111(2):140-144. doi: 10.1159/000449241. Epub 2016 Oct 19.

18.

Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.

Kantor D, Sotirchos ES, Calabresi PA.

Neurology. 2016 Sep 27;87(13):1424. doi: 10.1212/01.wnl.0000502811.31151.c9. No abstract available.

PMID:
27672169
19.

Ultrasound Guidance and Other Determinants of Successful Peripheral Artery Catheterization in Critically Ill Children.

Kantor DB, Su E, Milliren CE, Conlon TW.

Pediatr Crit Care Med. 2016 Dec;17(12):1124-1130.

20.

Rhinovirus and serum IgE are associated with acute asthma exacerbation severity in children.

Kantor DB, Stenquist N, McDonald MC, Schultz BJ, Hauptman M, Smallwood CD, Nelson KA, Perzanowski MS, Matsui EC, Phipatanakul W, Hirschhorn JN.

J Allergy Clin Immunol. 2016 Nov;138(5):1467-1471.e9. doi: 10.1016/j.jaci.2016.04.044. Epub 2016 Jun 15. No abstract available.

21.

Demonstration of equivalence of a generic glatiramer acetate (Glatopa™).

Anderson J, Bell C, Bishop J, Capila I, Ganguly T, Glajch J, Iyer M, Kaundinya G, Lansing J, Pradines J, Prescott J, Cohen BA, Kantor D, Sachleben R.

J Neurol Sci. 2015 Dec 15;359(1-2):24-34. doi: 10.1016/j.jns.2015.10.007. Epub 2015 Oct 8. Review.

22.

Looking for Tips on Central Venous Catheter Insertion? Try Ultrasound.

Su E, Kantor DB, Conlon T.

Pediatr Crit Care Med. 2015 Nov;16(9):891-3. doi: 10.1097/PCC.0000000000000517. No abstract available.

PMID:
26536557
23.

Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®.

D'Alessandro JS, Duffner J, Pradines J, Capila I, Garofalo K, Kaundinya G, Greenberg BM, Kantor D, Ganguly TC.

PLoS One. 2015 Oct 16;10(10):e0140299. doi: 10.1371/journal.pone.0140299. eCollection 2015.

24.

Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin: Interaction of Patient Demographics, Disease Characteristics, and Efficacy Outcomes.

Kantor D, Panchal S, Patel V, Bucior I, Rauck R.

J Pain. 2015 Dec;16(12):1300-1311. doi: 10.1016/j.jpain.2015.08.011. Epub 2015 Sep 25.

25.

First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.

Hughes B, Cascione M, Freedman MS, Agius M, Kantor D, Gudesblatt M, Goldstick LP, Agashivala N, Schofield L, McCague K, Hashmonay R, Barbato L; EPOC study investigators.

Mult Scler Relat Disord. 2014 Sep;3(5):620-8. doi: 10.1016/j.msard.2014.06.006. Epub 2014 Jul 3.

PMID:
26265274
26.

Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors.

Bermel RA, Hashmonay R, Meng X, Randhawa S, von Rosenstiel P, Sfikas N, Kantor D.

Mult Scler Relat Disord. 2015 May;4(3):273-80. doi: 10.1016/j.msard.2015.04.002. Epub 2015 Apr 13.

27.

Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis.

Kantor D, Chancellor MB, Snell CW, Henney HR 3rd, Rabinowicz AL.

Postgrad Med. 2015 Mar;127(2):218-22. doi: 10.1080/00325481.2015.1000229. Epub 2015 Jan 6.

PMID:
25560174
28.

Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.

Calkwood J, Cree B, Crayton H, Kantor D, Steingo B, Barbato L, Hashmonay R, Agashivala N, McCague K, Tenenbaum N, Edwards K.

BMC Neurol. 2014 Nov 26;14:220. doi: 10.1186/s12883-014-0220-1.

29.

Establishing intensivist-driven ultrasound at the PICU bedside--it's about time*.

Su E, Pustavoitau A, Hirshberg EL, Nishisaki A, Conlon T, Kantor DB, Weber MD, Godshall AJ, Burzynski JH, Thompson AE.

Pediatr Crit Care Med. 2014 Sep;15(7):649-52. doi: 10.1097/PCC.0000000000000168.

PMID:
24977438
30.

Intravenous β agonists and severe pediatric asthma exacerbation: time for a closer look at terbutaline?

Kantor DB, Phipatanakul W.

Ann Allergy Asthma Immunol. 2014 Mar;112(3):187. doi: 10.1016/j.anai.2014.01.005. No abstract available.

PMID:
24565592
31.

Novel therapeutics in multiple sclerosis management: clinical applications.

Leist T, Hunter SF, Kantor D, Markowitz C.

Am J Med. 2014 Jan;127(1):S2. doi: 10.1016/j.amjmed.2013.06.015.

PMID:
24384114
32.

Pulmonary hypertension associated with scurvy and vitamin deficiencies in an autistic child.

Duvall MG, Pikman Y, Kantor DB, Ariagno K, Summers L, Sectish TC, Mullen MP.

Pediatrics. 2013 Dec;132(6):e1699-703. doi: 10.1542/peds.2012-3054. Epub 2013 Nov 4.

33.

PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.

Brooks BR, Crumpacker D, Fellus J, Kantor D, Kaye RE.

PLoS One. 2013 Aug 21;8(8):e72232. doi: 10.1371/journal.pone.0072232. eCollection 2013.

34.

Replication and fine mapping of asthma-associated loci in individuals of African ancestry.

Kantor DB, Palmer CD, Young TR, Meng Y, Gajdos ZK, Lyon H, Price AL, Pollack S, London SJ, Loehr LR, Smith LJ, Kumar R, Jacobs DR Jr, Petrini MF, O'Connor GT, White WB, Papanicolaou G, Burkart KM, Heckbert SR, Barr RG, Hirschhorn JN.

Hum Genet. 2013 Sep;132(9):1039-47. doi: 10.1007/s00439-013-1310-7. Epub 2013 May 12.

35.

The impact of migraine on school performance.

Kantor D.

Neurology. 2012 Oct 30;79(18):e168-9. doi: 10.1212/WNL.0b013e3182745a97. No abstract available.

PMID:
23109661
36.

Routine dermatologist-performed full-body skin examination and early melanoma detection.

Kantor J, Kantor DE.

Arch Dermatol. 2009 Aug;145(8):873-6. doi: 10.1001/archdermatol.2009.137.

PMID:
19687416
37.

Theory vs. Practice.

Kantor D.

Am J Nurs. 2008 Jul;108(7):14; author reply 14. doi: 10.1097/01.NAJ.0000325796.29853.a3. No abstract available.

PMID:
18580111
38.

Methods for Improving Image Quality and Reducing Data Load of NIR Hyperspectral Images.

Firtha F, Fekete A, Kaszab T, Gillay B, Nogula-Nagy M, Kovács Z, Kantor DB.

Sensors (Basel). 2008 May 19;8(5):3287-3298.

39.

Cervical epidural blood patch for low CSF pressure headaches.

Kantor D, Silberstein SD.

Neurology. 2005 Oct 11;65(7):1138. No abstract available.

PMID:
16217080
40.

The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor selective for myelin-associated glycoprotein.

Venkatesh K, Chivatakarn O, Lee H, Joshi PS, Kantor DB, Newman BA, Mage R, Rader C, Giger RJ.

J Neurosci. 2005 Jan 26;25(4):808-22.

41.

Semaphorin 5A is a bifunctional axon guidance cue regulated by heparan and chondroitin sulfate proteoglycans.

Kantor DB, Chivatakarn O, Peer KL, Oster SF, Inatani M, Hansen MJ, Flanagan JG, Yamaguchi Y, Sretavan DW, Giger RJ, Kolodkin AL.

Neuron. 2004 Dec 16;44(6):961-75.

42.

Curbing the excesses of youth: molecular insights into axonal pruning.

Kantor DB, Kolodkin AL.

Neuron. 2003 Jun 19;38(6):849-52. Review.

43.

Improve your marketing effectiveness and net income through better prospecting.

Gombeski WR Jr, Kantor D, Bendycki NA, Wack J.

Health Mark Q. 2002;19(4):3-19.

PMID:
12557986
44.

Physician-based brand strategies.

Gombeski WR Jr, Kantor D, Klein R.

Mark Health Serv. 2002 Winter;22(4):28-34. No abstract available.

PMID:
12494797
45.

Breast cancer in older women: treatment, psychosocial effects, interventions, and outcomes.

Kantor DE, Houldin A.

J Gerontol Nurs. 1999 Jul;25(7):19-25; quiz 54-5. Review.

PMID:
10476127
46.

Recombinant adenovirus-mediated expression in nervous system of genes coding for ion channels and other molecules involved in synaptic function.

Ehrengruber MU, Lanzrein M, Xu Y, Jasek MC, Kantor DB, Schuman EM, Lester HA, Davidson N.

Methods Enzymol. 1998;293:483-503. No abstract available.

PMID:
9711625
47.
48.

A role for endothelial NO synthase in LTP revealed by adenovirus-mediated inhibition and rescue.

Kantor DB, Lanzrein M, Stary SJ, Sandoval GM, Smith WB, Sullivan BM, Davidson N, Schuman EM.

Science. 1996 Dec 6;274(5293):1744-8.

PMID:
8939872
49.

[Neuroleptic malignant syndrome in elderly hospital patients].

Kantor D, Dotan I, Kornowski R, Portnoy J.

Harefuah. 1994 Aug;127(3-4):85-7. Hebrew.

PMID:
7927043
50.

Adaptation of a psychiatric service to missile war.

Portnoy G, Kantor D, Bar-Natan E.

Gen Hosp Psychiatry. 1993 Nov;15(6):418-9. No abstract available.

PMID:
8112566

Supplemental Content

Loading ...
Support Center